Literature DB >> 15210544

Chronic inflammatory demyelinating polyradiculoneuropathy.

Ted M Burns1.   

Abstract

For much of the 20th century, our understanding of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was limited because the condition went by several different names; clinical and histopathologic descriptions were often combined with those of similar neuropathic disorders including Guillain-Barré syndrome, the hereditary hypertrophic polyneuropathies, and other chronic polyneuropathies; and the means to sufficiently study and treat the condition had not been developed. Major advances in the understanding of CIDP occurred mid century and included the development of the experimental allergic neuritis (EAN) model, the elaboration of nerve conduction studies, and the discovery of corticosteroids. In the 1970s, CIDP finally emerged as a distinct entity with well-defined clinical, histopathologic, and electrodiagnostic features. Diagnostic criteria were developed, and subsequent treatment trials proved the efficacy of corticosteroids, plasma exchange, and intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210544     DOI: 10.1001/archneur.61.6.973

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

Review 1.  Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Authors:  Amanda C Peltier; Peter D Donofrio
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

2.  Hypertrophic neuritis causing tetraparesis in a cat.

Authors:  Yui Kobatake; Hiroki Sakai; Hidetaka Nishida; Yosuke Uematsu; Sadatoshi Maeda; Hiroaki Kamishina
Journal:  J Vet Med Sci       Date:  2018-06-21       Impact factor: 1.267

Review 3.  Pathophysiology of the Different Clinical Phenotypes of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Authors:  Edyta Dziadkowiak; Marta Waliszewska-Prosół; Marta Nowakowska-Kotas; Sławomir Budrewicz; Zofia Koszewicz; Magdalena Koszewicz
Journal:  Int J Mol Sci       Date:  2021-12-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.